EE43 Subcutaneous or Intravascular Route of Administration for Natalizumab in Relapsing Remitting Multiple Sclerosis: Economic Appraisal of the Easier Study

To quantify the economic impact of the adoption of subcutaneous (SC) vs. intravascular (IV) natalizumab administration for the treatment of relapsing remitting multiple sclerosis (RRMS), from the perspectives of Italian patients, multiple sclerosis-centers (MS-centers), and Society.

Source: Value in Health - December 1, 2022 Category: International Medicine & Public Health Authors: M Filippi, L Grimaldi, A Conte, R Totaro, MR Valente, S Malucchi, F Granella, C Cordioli, V Brescia Morra, D Perini, L Santoni Source Type: research